Handelsbanken Fonder’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $986K | Sell |
27,123
-100
| -0.4% | -$3.64K | ﹤0.01% | 969 |
|
|
2025
Q1 | $986K | Hold |
27,223
| – | – | ﹤0.01% | 947 |
|
|
2024
Q4 | $1.15M | Buy |
27,223
+2,700
| +11% | +$114K | ﹤0.01% | 912 |
|
|
2024
Q3 | $1.36M | Buy |
24,523
+3,200
| +15% | +$178K | 0.01% | 815 |
|
|
2024
Q2 | $876K | Buy |
21,323
+6,700
| +46% | +$275K | ﹤0.01% | 897 |
|
|
2024
Q1 | $683K | Hold |
14,623
| – | – | ﹤0.01% | 1016 |
|
|
2023
Q4 | $699K | Hold |
14,623
| – | – | ﹤0.01% | 964 |
|
|
2023
Q3 | $521K | Hold |
14,623
| – | – | ﹤0.01% | 1032 |
|
|
2023
Q2 | $675K | Sell |
14,623
-3,000
| -17% | -$138K | ﹤0.01% | 910 |
|
|
2023
Q1 | $707K | Buy |
17,623
+5,400
| +44% | +$217K | ﹤0.01% | 832 |
|
|
2022
Q4 | $566K | Buy |
12,223
+1,700
| +16% | +$78.7K | ﹤0.01% | 900 |
|
|
2022
Q3 | $436K | Hold |
10,523
| – | – | ﹤0.01% | 1045 |
|
|
2022
Q2 | $628K | Hold |
10,523
| – | – | ﹤0.01% | 895 |
|
|
2022
Q1 | $764K | Hold |
10,523
| – | – | ﹤0.01% | 917 |
|
|
2021
Q4 | $885K | Hold |
10,523
| – | – | ﹤0.01% | 958 |
|
|
2021
Q3 | $949K | Hold |
10,523
| – | – | 0.01% | 933 |
|
|
2021
Q2 | $1M | Sell |
10,523
-600
| -5% | -$57.2K | 0.01% | 918 |
|
|
2021
Q1 | $1.27M | Buy |
11,123
+1,100
| +11% | +$125K | 0.01% | 743 |
|
|
2020
Q4 | $1.39M | Hold |
10,023
| – | – | 0.01% | 699 |
|
|
2020
Q3 | $824K | Buy |
10,023
+1,400
| +16% | +$115K | 0.01% | 788 |
|
|
2020
Q2 | $674K | Buy |
+8,623
| New | +$674K | 0.01% | 826 |
|
|
2016
Q4 | – | Sell |
-8,000
| Closed | -$568K | – | 169 |
|
|
2016
Q3 | $568K | Hold |
8,000
| – | – | 0.02% | 156 |
|
|
2016
Q2 | $391K | Hold |
8,000
| – | – | 0.02% | 168 |
|
|
2016
Q1 | $506K | Sell |
8,000
-8,000
| -50% | -$506K | 0.02% | 153 |
|
|
2015
Q4 | $1.8M | Buy |
+16,000
| New | +$1.8M | 0.03% | 370 |
|